Effect of Meta-Chlorophenylpiperazine (mCPP), A Central Serotonin Agonist and Vascular Serotonin Receptor Antagonist, on Blood Pressure in SHR

References

• Moser L R., Kaiser J A., Hardy R A., Jr. Process for producing anorexia. U. S. Patent 3, 253, 989
   Google Scholar
• Fong M H., Garattini S, Caccia S. 1-m-Chlorophenylpiperazine is an active metabolite common to the psychotropic drugs trazodone, etoperidone and mepiprazole. J Pharm Pharmacol 1982; 34: 674–675
   PubMed Web of Science ®Google Scholar
• Samanin R, Mennini T, Ferraris A, Bendotti C, Borsini F, Garattini S. m-Chlorophenylpiperazine: A central serotonin agonist causing powerful anorexia in rats. Naunyn-Schmiedeberg's Arch Pharmacol 1979; 308: 159–163
   Google Scholar
• Samanin R, Mennini T, Garattini S. Evidence that it is possible to cause anorexia by increasing release and/or directly stimulating postsynaptic serotonin receptors in the brain. Progr Neuro-Psychopharmacol. 1980; 4: 363–369
   PubMedGoogle Scholar
• Fuller R W., Mason N R., Molloy B B. Structural relationships in the inhibition of [3H]-serotonin binding to rat brain membranes in vitro by 1-phenylpiperazines. Biochem Pharmacol 1980; 29: 833–835
   PubMed Web of Science ®Google Scholar
• Fuller R W., Snoddy H D., Mason N R., Owen J E. Disposition and pharmacological effects of m-chlorophenylpiperazine in rats. Neuropharmacology 1981; 20: 155–162
   PubMed Web of Science ®Google Scholar
• Preziosi P, Cerrito F, Vacca M. Effects of naloxone on the secretion of prolactin and corticosterone induced by 5-hydroxy-tryptophan and a serotonergic agonist, mCPP. Life Sci 1983; 32: 2423–2430
   PubMed Web of Science ®Google Scholar
• Mueller E A., Murphy D L., Sunderland T. Neuroendocrine effects of m-chlorophenylpiperazine, a serotonin agonist, in humans. J Clin Endocrinol Metab 1985; 61: 1179–1184
   PubMed Web of Science ®Google Scholar
• Mueller E A., Murphy D L., Sunderland T, Jones J. A new postsynaptic serotonin receptor agonist suitable for studies in humans. Psychopharmacology Bulletin 1985; 21: 701–704
   PubMed Web of Science ®Google Scholar
• Heninger G R., Charney D S., Price L H. Clinical neurobiologic assessment of “presynaptic” and “postsynaptic” serotonergic function in major depression: effects of antidepressant treatment. Abstracts, Fourth World Congress of Biology Psychiatry. 1985; 131
   Google Scholar
• Heninger G R., Charney D S., Price L H. Neuroendocrine and behavioral effects of an i.v. infusion of a 5-HT1B agonist (mCPP) and L-tryptophan in rhesus monkeys, healthy humans and depressed patients. Abstracts, American College of Neuropsycho-pharmacology. 1985; 65
   Google Scholar
• Mueller E A., Murphy D L., Sunderland T. Further studies of the putative serotonin agonist, m-chlorophenylpiperazine: Evidence for a serotonin receptor mediated mechanism of action in humans. Psychopharmacol. 1986; 89: 388–391
   PubMed Web of Science ®Google Scholar
• Cohen M L., Fuller R W. Antagonism of vascular serotonin receptors by m-chlorophenylpiperazine and m-trifluoromethylphenyl-piperazine. Life Sci 1983; 32: 711–718
   PubMed Web of Science ®Google Scholar
• Sanders-Bush E, Conn P J. Effector systems coupled to serotonin receptors in brain: serotonin stimulated phosphoinositide hydrolysis. Psychopharmacol. Bull. 1986; 22: 829–836
   PubMed Web of Science ®Google Scholar
• Van Nueten J M., Janssen P AJ, Van Beek J, Xhonneux R, Verbeuren T J., Vanhoutte P M. Vascular effects of ketanserin (R41 468), a novel antagonist of 5HT2 serotonergic receptors. J Pharmacol Exp Ther 1981; 218: 217–230
   PubMed Web of Science ®Google Scholar
• Fozard J R. Mechanism of the hypotensive effect of ketanserin. J Cardiovasc Pharmacol 1982; 4: 829–838
   PubMed Web of Science ®Google Scholar
• Kalkman H O., Timmermans P BMWM, Van Zwieten P A. Characterization of the antihypertensive properties of ketanserin (R41 468) in rats. J Pharmacol Exper Ther 1982; 222: 227–231
   PubMed Web of Science ®Google Scholar
• Kalkman H O., Harms Y M., van Gelderen E M., Batink H D., Timmermans P BMWM, van Zwieten P A. Hypotensive activity of serotonin antagonists, correlation with α1-adrenoceptor and serotonin receptor blockade. Life Sci 1982; 32: 1499–1505
   Web of Science ®Google Scholar
• Cohen M L., Fuller R W., Kurz K D. Evidence that blood pressure reduction by serotonin antagonists is related to alpha receptor blockade in spontaneously hypertensive rats. Hypertension 1983; 5: 676–681
   PubMed Web of Science ®Google Scholar
• Cohen M L. Vascular serotonin receptors and blood pressure regulation. Drug Develop Res 1984; 4: 302–313
   Web of Science ®Google Scholar
• Murphy B F., Whitworth J A., Kincaid-Smith P. Ketanserin in the acute management of severe hypertension. J Cardiov Pharmacol 1985; 7: S168–S171
   PubMed Web of Science ®Google Scholar
• Woittez A JJ, Wenting G S., Man in'tVeld A J., Boomsma F, Schalekamp M ADH. Ketanserin: A possible tool for studying the role of serotonin in hypertension. J Cardiovas Pharmacol 1985; 7: S130–S136
   Web of Science ®Google Scholar
• Ramirez A J., Chemerinski E, Enero M A. Central serotonergic participation on blood pressure regulation. Gen Pharmac 1982; 13: 425–432
   Google Scholar
• Kuhn D M., Wolf W A., Lovenberg W. Review of the role of the central serotonergic neuronal system in blood pressure regulation. Hypertension 1980; 2: 243–255
   PubMed Web of Science ®Google Scholar
• Perry K W., Fuller R W. Analysis of biogenic amine metabolites in rat brain by HPLC with electrochemical detection. Soc Neurosci 1979; 348, Abstract 5
   Google Scholar
• Solem J H., Brinck-Johnsen T. An evaluation of a method for determination of free corticosteroids in minute quantities of mouse plasma. Scand J Clin Lab Invest 1965; 80: 1–14
   Google Scholar
• Vanhoutte P M. Platelets, serotonin and hypertension, a link?. Thromb Haemostasis 1985; 54: 321
   Web of Science ®Google Scholar
• Vanhoutte P M., Luscher L F. Serotonin and the blood vessel wall. J Hypertens 1986; 4: 29–35
   Web of Science ®Google Scholar
• Vanhoutte P M., Ball S G., Berdeaux A, Cohen M L., Hedner T, McCall R, Ramage A G., Reimann I H., Richer C, Saxena P R., Schalekamp M ADH, Struyker-Boudier H AJ, Symoens J, Van Nueten J M., Van Zwieten P A. Mechanism of action of ketanserin in hypertension. Trends in Pharmacol Sci 1986; 7: 58–59
   Web of Science ®Google Scholar
• Maj J, Lewandowska A. Central serotonin mimetic action of phenylpiperazines. Pol J Pharmacol Pharm 1980; 32: 495–504
   PubMedGoogle Scholar
• Rokosz-Pelc A, Antkiewicz-Michaluk L, Vetulani J. 5-Hydroxy-tryptamine-like properties of m-chlorophenylpiperazine: comparison with quipazine. J Pharm Pharmacol 1980; 32: 220–222
   PubMed Web of Science ®Google Scholar
• Di Renzo G, Schettini G, Amoroso S, Scopacasa F, Annunziato L, Quattrone A. Effect of m-chlorophenylpiperazine, a serotonin receptor agonist, on TSH secretion in the rat. Neuroendocrinol Lett 1982; 6: 329–333
   Google Scholar
• Davis M, Cassella J V., Wrean S H., Kehne J H. Sertonin receptor subtype agonists: Differential effects on sensorimotor reactivity measured with acoustic startle. Psychopharmacol. Bull. 1986; 22: 837–843
   PubMed Web of Science ®Google Scholar
• Sprouse J S., Aghajanian G K. Serotonergic dorsal raphe neurons: Electrophysiological responses in rats to 5-HT1A and 5-HT1B receptor subtype ligands. Soc. Neurosci. Abstr. 1985; 11: 47
   Google Scholar
• Sills M A., Wolfe B B., Frazer A. Determination of selective and nonselective compounds for the 5-HT1A and 5-HT1B receptor subtypes in rat frontal cortex. J. Pharmacol. Exp. Ther. 1984; 231: 480–487
   PubMed Web of Science ®Google Scholar
• Hamon H, Cossery J- M., Spampinato U, Gozlan H. Are there selective ligands for 5-HT1A and 5-HT1B receptor binding sites in brain?. Trends in Pharmacol. Sci. 1986; 7: 336–338
   Web of Science ®Google Scholar
• Fuller R W., Yen T T., Stamm N B. Lowering of blood pressure by direct-and indirect-acting serotonin agonists in spontaneously hypertensive rats. Clin Exper Hyperten 1981; 3: 497–508
   PubMed Web of Science ®Google Scholar
• Bunag R D. Facts and fallacies about measuring blood pressure in rats. Clin Exp Hypertension 1983; 5(10)1659–1681
   Web of Science ®Google Scholar
• Martin G E., Lis E V., Jr. Hypotensive action of 8-hydroxy-2-(di-N-propylamino)tetralin (8-OH-DPAT) in spontaneously hypertensive rats. Arch. int. Pharmacodyn. Ther. 1985; 273: 251–261
   PubMedGoogle Scholar